tiprankstipranks
Advertisement
Advertisement

ARTV Stock Latest News

Artiva Biotherapeutics Announces Major Executive Leadership Transitions
Company AnnouncementsArtiva Biotherapeutics Announces Major Executive Leadership Transitions
2d ago
8K
ARTV
Artiva Biotherapeutics price target raised to $41 from $18 at Needham
PremiumThe Fly
Artiva Biotherapeutics price target raised to $41 from $18 at Needham
9d ago
ARTV
Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush
PremiumThe Fly
Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush
10d ago
ARTV
Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial
PremiumRatings
Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial
10d ago
ARTV
Artiva Biotherapeutics Announces $300 Million Equity Offering
PremiumCompany Announcements
Artiva Biotherapeutics Announces $300 Million Equity Offering
13d ago
8K
ARTV
Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright
PremiumThe FlyArtiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright
13d ago
ARTV
Artiva Highlights AlloNK RA Data and Phase 3 Alignment
Premium
Company Announcements
Artiva Highlights AlloNK RA Data and Phase 3 Alignment
13d ago
8K
ARTV
Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)
Premium
The Fly
Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)
13d ago
ARTV
Artiva reports data from clinical trials evaluating AlloNK
PremiumThe Fly
Artiva reports data from clinical trials evaluating AlloNK
13d ago
ARTV
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts
PremiumRatings
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts
2M ago
ARTV
Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating
PremiumRatings
Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating
2M ago
ARTV
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer
PremiumCompany Announcements
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer
3M ago
8K
ARTV
Artiva Biotherapeutics appoints Huston as Chief Financial Officer
PremiumThe FlyArtiva Biotherapeutics appoints Huston as Chief Financial Officer
3M ago
ARTV
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board
Premium
Company Announcements
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board
3M ago
8K
ARTV
Artiva Biotherapeutics appoints Sorg to board of directors
Premium
The Fly
Artiva Biotherapeutics appoints Sorg to board of directors
3M ago
ARTV
Artiva (ARTV): Off‑the‑Shelf AlloNK Platform Positions Lead RA Program for Pivotal De‑Risking and Attractive Risk‑Reward
PremiumRatings
Artiva (ARTV): Off‑the‑Shelf AlloNK Platform Positions Lead RA Program for Pivotal De‑Risking and Attractive Risk‑Reward
3M ago
ARTV
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & Ideas
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
5M ago
ARTV
BCRX
Artiva Biotherapeutics Executes RSU Exchange for Employees
PremiumCompany Announcements
Artiva Biotherapeutics Executes RSU Exchange for Employees
5M ago
8K
ARTV
Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development
PremiumCompany Announcements
Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development
6M ago
ARTV
Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases
PremiumRatingsPromising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases
6M ago
ARTV
Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge
Premium
Ratings
Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge
6M ago
ARTV
Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results
Premium
Ratings
Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results
6M ago
ARTV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >